|
1. Biologie
|
|
|
|
3. Prévention
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
3.7 Prévention - Alcool
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
|
|
Roche's Tecentriq cocktail adds to lung cancer survival success [Reuters]
|
|
|
|
|
|
The
world’s biggest maker of cancer drugs is counting on growing sales of
Tecentriq (atezolizumab), which notched 487 million Swiss francs in
2017, to help offset falling revenue from its older cancer medicines
Avastin, Rituxan and Herceptin whose patent expirations are exposing
them to rivals’ cheaper copies.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
Peter Thiel's Firm Backed A Biotech. Big Pharma Bought It. It Blew Up [Forbes]
|
|
|
|
|
|
Timothy
Anderson, an analyst at Bernstein Research, wrote that drugs like
Merck's Keytruda and Bristol-Myers Squibbs Opdivo seem to have
competitive results and don't require a diagnostic test for a protein
called DLL3, which Rova-T does. AbbVie shares are down 15%. All this
would just be another failure, albeit a risky one, were it not for
comments that Thiel made about how Stemcentrx was more like software
when the company started to make noise three years ago.
|
|
|
|
|
|
|
|
AbbVie's lung cancer drug data disappoints; shares slump [Reuters]
|
|
|
|
|
|
Guggenheim
Securities analyst Tony Butler said AbbVie will likely have to run a
bigger trial that will cost more and will need to have a control arm.
“They wanted to do this with a relatively small number of patients and
not have to run a control or a big study. That strategy is now thrown
out.”
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.9 AACR
|
|
|
|
5.9.1 AACR - sein
|
|
|
|
5.9.5 AACR - CAR-T
|
|
|
Improving the Effectiveness of CAR T-cell Immunotherapy [Cancer Research Catalyst]
|
|
|
|
|
|
“Based
on these data, we have altered our practice for T-cell collection for
children with leukemia, for children with high-risk disease … we will
collect T cells early even if that patient is not currently eligible for
CAR trial simply because we know that cumulative therapy is going to
progressively deteriorate the likelihood that the cells will make a
functional CAR product.
|
|
|
|
|
|
|
|
5.9.7 AACR - divers
|
|
|
Chlamydia Infection is Associated With Increased Risk of Ovarian Cancer [AACR]
|
|
|
|
|
|
The
researchers examined data from two different studies: a Polish study of
278 women diagnosed with ovarian cancer between 2000 and 2003, and 556
matched controls; and the NCI-sponsored Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial, a nested case-control study with blood
draw prior to diagnosis which included 160 women who developed ovarian
cancer during follow-up, and 159 matched controls.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
ASCO Commends Congress for Passing Largest NIH Funding Increase in 15 Year [ASCO]
|
|
|
|
|
|
Building
on federal funding increases over the past two years, the $5.9 billion
allocated to the National Cancer Institute, including $300 million
authorized in the 21st Century Cures Act, demonstrates lawmakers'
sustained commitment to investing in biomedical innovation that will
deliver the next generation of cancer cures to individuals with cancer
and give hope to the millions of Americans who face a cancer diagnosis
each year.
|
|
|
|
|
|
|
|
6.2 Implants mammaires
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Israel to launch Big Data health project [Reuters]
|
|
|
|
|
|
Nadav
Davidovitch, head of the Public Health School at Ben Gurion University
in southern Israel, said the country’s push to harness big data for
healthcare had huge potential, but also held risks in terms of privacy
and medical confidentiality.
|
|
|
|
|
|
|
6.8 Communication
|
|
|
How Social Media Can Reveal Overlooked Drug Reactions [NPR]
|
|
|
|
|
|
Collecting
data about a drug from insurance claims and health records typically
happens with quite a time lag. So mining the Internet and social media
for casual patient reports is tempting, Kesselheim says, because of its
potential scale and speed. But the approach also has drawbacks.
|
|
|
|
|
|